Search results for Brolucizumab

Brolucizumab Biosimilar – Anti-VEGFA mAb – Research Grade, ProteoGenix, PX-TA1374

Description of Brolucizumab Biosimilar - Anti-VEGFA mAb - Research Grade General information on Anti-VEGFA[Homo sapiens] (Brolucizumab) Monoclonal Antibody Brolucizumab is a monoclonal antibody used to treat neovascular age related macular degeneration.

Brolucizumab, Abbexa, abx831334

Brolucizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting VEGFA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Brolucizumab, also known as RTH258 or ESBA1008, 4 is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019. 6.

Brolucizumab, Kyinno, KB-1523

Brolucizumab Antibody, Abbexa, abx376607

Brolucizumab Antibody is a rabbit polyclonal antibody for the detection of Brolucizumab.

Brolucizumab ELISA Kit, Abbexa, abx395077

Brolucizumab ELISA Kit is a quantitative ELISA kit for detection of Brolucizumab.Brolucizumab is the first and only single-chain variable fragment (scFv) targeting vascular endothelial growth factor (VEGF)-A. It has a smaller molecular weight (26 kDa). The mAb is undergoing evaluation as a treatment for neovascular age-related macular degeneration (nAMD). In June 2017, Novartis announced that the primary efficacy endpoint of non-inferiority to aflibercept (EYLEA®) in mean change in best-corrected visual acuity from baseline to week 48 was met in the Phase 3 HAWK (NCT02307682) and HARRIER (NCT02434328) studies, which included more than 1,800 patients. The two studies compared the efficacy and safety of intravitreal injections of 6 mg brolucizumab or 3 mg brolucizumab (HAWK study only) versus 2 mg aflibercept in patients with nAMD. Of patients receiving 6 mg brolucizumab, 57% (HAWK) and 52% (HARRIER) were maintained exclusively on an every 12 week dosing interval immediately following the loading phase and continuing through week 48.54 Key secondary endpoints were also met. Novartis is developing a competitive, low cost of goods formulation, and expects to complete the PK study with antibody derived from the final manufacturing process to enable filing in 2018.

Anti-Brolucizumab Polyclonal Antibody, AntibodySystem, PAD12603